BPC-157 TB-500
Blend Wholesale
The most purchased healing peptide combination in wholesale research supply. BPC-157 (5mg) and TB-500 (5mg) co-lyophilized in a single vial — one reconstitution, two complementary repair mechanisms, zero protocol friction. HPLC-verified ≥98% purity on both peptides, full COA every batch.
The BPC-157 TB-500 Blend — Why It’s the #1 Healing Stack
The BPC-157 TB-500 blend — commonly referred to as the “Wolverine Stack” in research and sports medicine circles — is the most purchased healing peptide combination in wholesale research supply. Its dominance is not marketing: it reflects a genuine pharmacological rationale. BPC-157 and TB-500 operate through distinct, non-overlapping molecular mechanisms that are structurally complementary in the tissue repair cascade. Together they cover the full repair sequence from initiation to remodeling in ways neither peptide achieves independently.
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid gastric pentadecapeptide acting primarily through VEGFR2 internalization, FAK-paxillin signaling, and nitric oxide pathway modulation. It initiates vascular repair, stabilizes endothelial function, and recruits fibroblasts to injury sites — the upstream phase of tissue repair. TB-500 (synthetic Thymosin Beta-4 fragment, Ac-LKKTETQ-NH₂) is a 43-amino-acid actin-sequestering peptide that promotes systemic cell migration, cytoskeletal reorganization, and extracellular matrix remodeling — the downstream amplification phase. The mechanistic division of labor between them is the scientific basis for the blend’s research popularity.
For wholesale buyers, the pre-made blend offers a critical operational advantage: one SKU replaces two, one COA covers both peptides, one reconstitution delivers the complete protocol dose, and one order line manages the entire healing stack supply chain. For high-volume clinics and research programs running consistent 5mg+5mg protocols, this simplification is a meaningful operational benefit.
Complementary Mechanisms
BPC-157 and TB-500 do not duplicate each other’s actions. BPC-157 operates via VEGFR2, FAK-paxillin, and NO pathways — local vascular and tissue initiation. TB-500 operates via actin sequestration and systemic cell migration — amplification and remodeling. This non-redundancy is the pharmacological rationale for the combination.
One Vial, Zero Friction
Co-lyophilized means both peptides are combined before freeze-drying — one vial, one reconstitution, consistent ratio delivery. Eliminates the protocol complexity of managing two separate SKUs, two reconstitutions, two storage timelines, and two order lines. Critical for high-volume wholesale programs.
#1 Healing Combo in Wholesale
The BPC-157 TB-500 stack generates 60,000+ combined monthly searches in wholesale-intent terms. It consistently ranks as the highest-volume healing peptide blend SKU in B2B peptide wholesale supply — driven by repeat-purchase patterns from sports medicine, physical therapy research, and regenerative medicine programs.
Better Value Than Buying Separate
Blend pricing is structured to offer better per-mg value than purchasing BPC-157 and TB-500 as separate SKUs at individual pricing. Volume pricing at 10, 25, and 50+ vials reduces per-unit cost further — making the blend the right choice for any wholesale buyer running consistent 5mg+5mg protocols.
BPC-157 + TB-500 — How the Two Mechanisms Combine
The case for the BPC-157 TB-500 combination rests on the mechanistic division of labor between the two peptides at different phases of the tissue repair process. Neither peptide replicates the other’s primary mechanism — they address different cellular targets, different signaling pathways, and different phases of repair.
Modality
Repair
Vascular Stabilization
BPC-157 initiates repair by activating VEGFR2 and the nitric oxide pathway, stabilizing endothelial function and establishing new microvascular networks to restore blood flow and oxygenation to the injury site. This is the prerequisite for effective cellular repair.
Cellular Recruitment
BPC-157 recruits fibroblasts via FAK-paxillin signaling and elevates EGR-1 for collagen precursor synthesis. TB-500 simultaneously amplifies endothelial and keratinocyte migration via actin dynamics, delivering repair cells to the vascularized injury site at scale.
Matrix Remodeling
TB-500 drives the final remodeling phase through stem cell differentiation, organized collagen architecture, and anti-apoptotic signaling. The result — documented in preclinical models — is faster recovery, organized extracellular matrix structure, and durable tissue integration.
Pre-Made Blend vs Buying BPC-157 & TB-500 Separately
For wholesale buyers running consistent 5mg+5mg protocols, the pre-made blend is the operationally superior choice. Here’s why:
| Factor | Pre-Made Blend | Separate SKUs |
|---|---|---|
| SKUs to manage | 1 SKU | 2 SKUs |
| Reconstitutions per dose | 1 | 2 |
| COAs to review | 1 (covers both peptides) | 2 separate COAs |
| Order lines | 1 | 2 |
| Ratio consistency | Fixed 1:1 — guaranteed | Depends on separate prep |
| Per-mg value vs singles | Better at volume | Standard single-peptide pricing |
| Storage management | One vial type, one temp | Two vial sets to track |
| Best for | Fixed 5+5mg protocol programs | Variable ratio research protocols |
The only scenario where buying separate is preferable: research protocols requiring variable peptide ratios (e.g., 10mg BPC-157 with 5mg TB-500, or BPC-157-only phases). For standard 5mg+5mg healing stack protocols — which represent the majority of wholesale demand — the blend is the right call.
BPC-157 TB-500 Blend — Full Specifications
Both peptides are verified independently before blending. COA documentation covers both peptide components and is available prior to purchase.
BPC-157 Component
| Full Name | Body Protection Compound 157 |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Amino Acids | 15 |
| Molecular Weight | 1,419.53 Da |
| CAS Number | 137525-51-0 |
| Amount Per Vial | 5mg |
TB-500 Component
| Full Name | Thymosin Beta-4 (synthetic fragment) |
| Active Sequence | Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln… |
| Amino Acids | 43 |
| Molecular Weight | 4,963.44 Da |
| CAS Number | 77591-33-4 |
| Amount Per Vial | 5mg |
Blend Format
| Total Content | 10mg per vial (5mg BPC-157 + 5mg TB-500) |
| Form | Co-lyophilized powder |
| Blend Ratio | 1:1 (equal mass) |
| Solubility | Bacteriostatic water |
| Storage | -20°C · up to 24 months |
| Post-reconstitution | 4°C · use within 28 days |
Quality Standards
| HPLC Purity | ≥98% (both peptides verified) |
| Identity | Mass spec for each peptide |
| Endotoxin | <1 EU/mg (LAL method) |
| Sterility | Sterile-filtered, aseptic fill |
| TFA Content | Tested & reported on COA |
| Water Content | <5% (Karl Fischer) |
BPC-157 TB-500 Blend Wholesale Price — Volume Tiers 2026
Blend pricing is structured for clinic-scale and institutional wholesale buyers. All tiers include full COA documentation covering both peptide components.
| Quantity | Total Price | Per Vial | Per mg (total) | Availability |
|---|---|---|---|---|
| Blend 5+5mg × 1 | $68 | $68 | $6.80 / mg | ✓ In Stock |
| Blend 5+5mg × 10CLINIC PACK | $600 | $60 | $6.00 / mg | ✓ In Stock |
| Blend 5+5mg × 25 | $1,400 | $56 | $5.60 / mg | ✓ In Stock |
| Blend 5+5mg × 50 | $2,600 | $52 | $5.20 / mg | ✓ In Stock |
| Blend 5+5mg × 100+ | Contact | Custom | Custom rate | ✓ In Stock |
BPC-157 & TB-500 in Preclinical Research
Both peptides have independent preclinical research bases. Note: no published human RCT has studied BPC-157 and TB-500 in combination — the blend’s research rationale is derived from their complementary individual mechanisms and the multi-phase tissue repair model documented in their respective preclinical literature.
BPC-157 — Musculoskeletal Repair Research
Rat Achilles transection models have consistently demonstrated accelerated tendon healing with BPC-157, with load-to-failure recovery 30–50% faster than controls. Quadriceps detachment models showed structural and functional recovery in BPC-157-treated groups not observed in controls. The FAK-paxillin and VEGFR2 mechanisms underlying these effects are well-characterized in the published literature.
Extensive publication record in Journal of Orthopaedic Research, Knee Surgery Sports Traumatology, Frontiers in Pharmacology
TB-500 — Cell Migration & Cardiac Repair Research
TB-500 (Thymosin Beta-4 fragment) has been studied in cardiac repair models following myocardial infarction, demonstrating improved cardiac muscle survival and function in preclinical studies. Corneal wound healing research documented accelerated wound closure and cytokine modulation. The actin-sequestration mechanism driving endothelial and keratinocyte migration is established in the published Thymosin Beta-4 literature.
Published in Circulation, Journal of Investigative Dermatology, Molecular Biology of the Cell
Actin Synergy — BPC-157 Axin Upregulation + TB-500 Actin Binding
A mechanistically important finding: BPC-157 has been shown to upregulate axin gene transcription and increase actin production at the gene level, while TB-500 is an actin-binding peptide that sequesters and redistributes actin to areas of maximum cellular movement need. This axin-actin axis creates a molecularly coherent rationale for the combination — BPC-157 produces the actin substrate, TB-500 directs it — documented in published preclinical research.
Published in Biotech Peptides research summary, citing preclinical molecular biology findings
Anti-Inflammatory Convergence
Both peptides independently demonstrate anti-inflammatory activity in preclinical models — BPC-157 through TNF-α and IL-6 downregulation, TB-500 through NFκB pathway modulation and PMN infiltration reduction. Their convergent anti-inflammatory actions at different signaling nodes creates a broader anti-inflammatory profile than either peptide provides alone, a key rationale for combination use in inflammatory tissue injury research protocols.
BPC-157: Sikiric et al., Inflammopharmacology; TB-500: Corneal model publications, NFκB inflammatory research
Blend Quality Standards — What a Real COA Covers
A COA for a peptide blend must cover both components independently — not just one. Many blend suppliers provide a single aggregate purity figure that tells you nothing about the individual peptide quality. Our COA breaks down each component separately.
Dual-Component COA
COA covers BPC-157 and TB-500 independently — separate HPLC, separate mass spec. Pre-purchase available.
Both ≥98% HPLC
Each peptide verified at ≥98% purity before blending. Not a blended aggregate — individual verification.
Endotoxin + Sterility
LAL endotoxin <1 EU/mg. Sterile-filtered blend, aseptic fill. TFA content reported for both peptides.
Co-Lyophilized
Both peptides combined prior to lyophilization. Verified consistent ratio across the vial — not a physical mix.
Cold-Chain Shipping
Ships cold-chain. -20°C stable 24+ months. Both peptides stable in co-lyophilized format.
48h Fulfillment
In-stock orders ship within 48 business hours with cold-chain manifest and tracking.
Who Buys BPC-157 TB-500 Blend Wholesale
The blend’s high repeat-purchase rate is driven by consistent institutional demand from programs running fixed 5+5mg healing protocols. Not available to the general public.
Sports Medicine Practices
The highest repeat-purchase buyer category. Fixed 5+5mg musculoskeletal recovery protocols create consistent monthly ordering cycles.
Physical Therapy Research Programs
PT research centers studying tissue repair and recovery optimization running standardized blend protocols.
Regenerative Medicine Clinics
Regenerative practices running multi-tissue repair research protocols under physician oversight.
Research Institutions & CROs
Preclinical research programs studying dual-peptide synergy in musculoskeletal, vascular, or cardiac repair models.
Longevity Practices
Anti-aging and longevity programs incorporating healing stack protocols alongside metabolic and hormonal research.
Peptide Distributors
B2B distributors supplying downstream licensed buyers. The blend is a high-velocity SKU with built-in repeat demand.
BPC-157 TB-500 Blend Wholesale — FAQ
Research Use Only: BPC-157 TB-500 blend and all products listed on this page are sold strictly for in vitro research and laboratory use only. Not intended for human or veterinary use, consumption, injection, or therapeutic application. Not FDA-approved drugs or dietary supplements. BPC-157 is on the FDA 503A Category 2 bulks list and is not available for compounding pharmacy use. No claims are made regarding safety, efficacy, or therapeutic benefit in humans or animals. Buyers are solely responsible for compliance with all applicable federal, state, and local laws. By purchasing, you confirm you are a licensed researcher or qualified institutional buyer acting within the scope of a legitimate research program.
Reviews
There are no reviews yet.